VRDN Q4 2021 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$214,000+296.3% YoY

Gross Profit

-$22M-10364.5% margin

Operating Income

-$29M-13589.3% margin

Net Income

-$29M-13526.2% margin

EPS (Diluted)

$-2.59

QoQ Revenue Growth

+2.9%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$204M

Total Liabilities

$16M

Stockholders' Equity

$188M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$214,000	$54,000	+296.3%
Gross Profit	-$22M	-$15M	-45.9%
Operating Income	-$29M	-$91M	+67.9%
Net Income	-$29M	-$91M	+68.1%

Revenue Segments

Collaboration Revenue

$3M100%